Fulvestrant in treatment for metastatic breast cancer

Fulvestrant in treatment for metastatic breast cancer

Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic therapy replacements. Hormonal therapy shows its therapeutic efficacy with less toxicity and a better quality of life for patients compared wi...

Full description

Bibliographic Details
Main Authors:	L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, A. E. Storozhakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. L’yanova, L. A. Ryadinskaya, M. O. Ezhova, M. A. Teplyakova, L. K. Strakhov
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2019-12-01
Series:	Медицинский совет
Subjects:	metastatic hormone-positive breast cancer fulvestrant hormonal therapy adverse events toxicity
Online Access:	https://www.med-sovet.pro/jour/article/view/5157

Similar Items

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
by: Indhuja Muthiah Vaikundaraja, et al.
Published: (2020-01-01)

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience
by: Samitha Andrahennadi, et al.
Published: (2021-08-01)

Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety
by: I. A. Koroleva, et al.
Published: (2020-07-01)

Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice
by: L. Yu. Vladimirova, et al.
Published: (2019-06-01)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020-06-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
by: L. Yu. Vladimirova, et al.
Published: (2021-08-01)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
by: Yukinori Ozaki, et al.
Published: (2022-01-01)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
by: Kamila Kaminska, et al.
Published: (2021-02-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
by: Mi Hwa Heo, et al.
Published: (2019-09-01)

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report
by: Joan Manel Gasent Blesa, et al.
Published: (2009-04-01)

A method to detect fulvestrant interference in estradiol in breast cancer patients
by: Margarida Brito, et al.
Published: (2023-10-01)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
by: Alyssa Schlotman, et al.
Published: (2020-03-01)

Effect of the prenatal action of fulvestrant on the ovaries of the offspring of laboratory mice
by: Rimma T. Sulaymanova
Published: (2021-12-01)

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
by: Fulvio Borella, et al.
Published: (2023-08-01)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
by: Xing Huang
Published: (2019-11-01)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
by: Misato Masuyama, et al.
Published: (2023-09-01)

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
by: Ryan M. Finnegan, et al.
Published: (2023-01-01)

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa
by: Nabawanuka A, et al.
Published: (2018-10-01)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
by: Lauren Darrigues, et al.
Published: (2021-03-01)

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
by: D. A. Filonenko, et al.
Published: (2021-12-01)

Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis
by: Ying Hui, et al.
Published: (2015-07-01)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
by: Abdel-Razeq H, et al.
Published: (2022-03-01)

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy
by: A. A. Lyanova, et al.
Published: (2020-07-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy
by: L. Yu. Vladimirova, et al.
Published: (2022-06-01)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
by: Valentina Rossi, et al.
Published: (2019-10-01)

Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
by: Cheng Liu, et al.
Published: (2020-10-01)

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
by: M. A. Frolova, et al.
Published: (2018-07-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
by: Carla L. Alves, et al.
Published: (2018-06-01)

A novel UPLC-PDA isocratic method for the quantification fulvestrant in oil-based pre-filled syringe injection matrix formulations
by: Thirupathi Dongala, et al.
Published: (2019-03-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
by: Tong Xu, et al.
Published: (2022-05-01)

Dynamics of changes in expression of VEGF neoangiogenic factor in tumor tissue bioptates in patients with squamous cell carcinoma of oral mucosa receiving cetuximab treatment and chemotherapy
by: A. A. Lyanova, et al.
Published: (2022-12-01)

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
by: Fulbert Fu, et al.
Published: (2022-03-01)